< Back to previous page
Publication
Cost-utility analysis of ranibizumab (lucentis®) in wet-AMD based on real-life data collected in the HELIOS study after ranibizumab reimbursement in Belgium
Book Contribution - Book Abstract Conference Contribution
Subtitle:Cost-utility analysis of ranibizumab (lucentis (R)) in wet-AMD based on real-life data collected in the HELIOS study after ranibizumab reimbursement in Belgium
Book: VALUE IN HEALTH
Volume: 14
Pages: A55 - A55
Publication year:2011
Accessibility:Closed